Product Details
- Product Name: Olanzapine for Injection
- Strength: 10 mg/vial
- Presentation: Single-Dose Vial
- Bioequivalence: The product is bioequivalent and therapeutically equivalent to the reference listed drug Zyprexa® IntraMuscular Injection 10 mg/vial
- Reference Drug Manufacturer: Cheplapharm Registration GmbH
- Reference NDA: 021253
Market Context
According to IQVIA® sales data for the 12-month period ending May 2026, the Zyprexa® IntraMuscular Injection market (including brand and all available therapeutic equivalents) achieved annual sales of approximately $25.4 million. The data note specifies that IQVIA data obtained by Glenmark is only available for all approved RLD indications, while Glenmark's product is only approved for the indications listed in Glenmark's approved label, which may differ from the RLD indications.
Strategic Rationale
Marc Kikuchi, President & Business Head, North America, stated that the launch underscores the company's strategic focus on growing a robust injectables portfolio and strengthening presence within the institutional channel. It reflects the company's commitment to expanding access to quality and affordable treatment options.
Company Background
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is described as a global, research-led pharmaceutical company with 11 world-class manufacturing facilities across four continents, six R&D centres, and commercial footprint in 80+ countries. The company focuses on respiratory, dermatology, and oncology therapeutic areas and is positioned among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024 (Scrip 100).